logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
A

Akira Ono

Shizuoka Cancer Center
H指数:36
被引数:4,781

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Amivantamab plus chemotherapy versus chemotherapy for first-line treatment of participants with EGFR exon 20 insertion-mutated advanced non-small cell lung cancer: PAPILLON Asia subgroup analysis

Amivantamab联合化疗与化疗一线治疗EGFR外显子20插入突变的晚期非小细胞肺癌患者: PAPILLON Asia亚组分析

Lung Cancer
IF4.4
2026-02-020
PRE
Caicun Zhou; Ke-Jing Tang; Baogang Liu; Sang-We Kim; Satoru Kitazono; Akira Ono; Muthukkumaran Thiagarajan; Jen-Yu Hung; Michael Boyer; Timuçin Çİl; Yu Yao; Rajnish Nagarkar; John Xie; Archan Bhattacharya; Honeylet Wortman-Vayn; Mahadi Baig; Trishala Agrawal; Patricia Lorenzini; Se-Hoon Lee; Byoung Chul Cho
Initial Patient Characteristics Associated With Ineligibility for Second-Line Therapy After Progression on First-Line Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer

EGFR突变非小细胞肺癌患者在使用奥希替尼一线治疗后进展，与二线治疗不适用相关的初始患者特征

THORACIC CANCER
IF2.3
2025-11-170
OAAI
Kodama, Hiroaki; Murakami, Haruyasu; Mamesaya, Nobuaki; Kobayashi, Haruki; Wakuda, Kazushige; Ko, Ryo; Ono, Akira; Kenmotsu, Hirotsugu; Naito, Tateaki; Shimizu, Tetsuo; Gon, Yasuhiro; Takahashi, Toshiaki
Amivantamab-Chemotherapy in Non-Small Cell Lung Cancer with EGFR Exon 20 Insertions: Impact of Treatment Crossover and Other Endpoints from the Phase III PAPILLON Study

Amivantamab-化疗在EGFR外显子20插入的非小细胞肺癌中的应用：来自III期PAPILLON研究的治疗交叉和其他终点的影响

Targeted Oncology
IF4
2025-11-030
OAAI
Rachel E. Sanborn; Caicun Zhou; Ke-Jing Tang; Byoung Chul Cho; Susanna Cheng; Sanjay Popat; Akira Ono; Shun Lu; Margarita Majem; Andres Aguilar; Maria Del Rosario Garcia Campelo; Hidetoshi Hayashi; Kang-yun Lee; Se-Hoon Lee; Angelo Delmonte; Jorge Alatorre-Alexander; Gary Richardson; Victor Santos; Christophe Dooms; Joshua K. Sabari; Catherine A. Shu; Nicolas Girard; Aaron S. Mansfield; Keunchil Park; Yichuan Xia; Archan Bhattacharya; Nasuh Buyukkaramikli; Nolen Perualila; Joris Diels; Sandip Acharya; Conor Chandler; Irina Proskorovsky; Lindsay Dearden; Honeylet Wortman-Vayn; Parthiv J. Mahadevia; Roland E. Knoblauch; Trishala Agrawal; Mahadi Baig; Enriqueta Felip
Patient-reported outcomes and time to symptomatic progression from PAPILLON: amivantamab plus chemotherapy vs chemotherapy as first-line treatment of EGFR exon 20 insertion-mutated advanced NSCLC

患者报告结局和症状进展时间来自PAPILLON研究：amivantamab联合化疗对比化疗作为表皮生长因子受体（EGFR）外显子20插入突变型晚期非小细胞肺癌的一线治疗

Lung Cancer
IF4.4
2025-10-030
PRE
Luis Paz-Ares; Remi Veillon; Margarita Majem; Caicun Zhou; Ke-Jing Tang; Sang-We Kim; Gary Richardson; Nicolas Girard; Rachel E. Sanborn; Aaron S. Mansfield; Keunchil Park; Julia Schuchard; Joris Diels; Jan Sermon; Archan Bhattacharya; Patricia Lorenzini; Honeylet Wortman-Vayn; Roland E. Knoblauch; Trishala Agrawal; Mahadi Baig; Akira Ono; Joshua K. Sabari
Amivantamab Plus Chemotherapy in Japanese Patients With EGFR Exon 20 Insertions NSCLC

Amivantamab联合化疗在日本EGFR外显子20插入突变非小细胞肺癌患者中的应用

Cancer Science
IF4.3
2025-09-080
OAAI
Satoru Kitazono; Akira Ono; Tetsuji Kawamura; Osamu Hataji; Hiroshi Tanaka; Shingo Matsumoto; Naohiro Watanabe; Hiromi Nagashima; Masahide Oki; Michiko Takahashi; Tomoko Anazawa; Takahiro Shirai; Aimi Yamashita; Honeylet Wortman-Vayn; Archan Bhattacharya; Trishala Agrawal; Mahadi Baig; Roland E. Knoblauch; Hidetoshi Hayashi
Phase II study of afatinib for advanced non-small cell lung cancer with uncommon epidermal growth factor receptor mutations, including compound mutations detected by next-generation sequencing

II期研究：阿法替尼治疗携带罕见表皮生长因子受体突变（包括由下一代测序检测到的复合突变）的晚期非小细胞肺癌

international journal of oncology
IF2.8
2025-07-060
PRE
Nobuaki Mamesaya; Keita Mori; Haruki Kobayashi; Shota Omori; Ryo Ko; Kazushige Wakuda; Akira Ono; Hirotsugu Kenmotsu; Tateaki Naito; Haruyasu Murakami; Toshiaki Takahashi
Single-arm multicenter phase II study on aggressive local consolidative therapy in combination with systemic chemotherapy for stage IV non-small cell lung carcinoma with oligometastases: CURE-OLIGO (TORG1529)
RADIATION ONCOLOGY
IF3.2
2025-01-040
OAAI
Tokito, Takaaki; Yamada, Kazuhiko; Ishii, Hidenobu; Takiguchi, Yuichi; Saito, Go; Minato, Koichi; Imai, Hisao; Tanaka, Hiroshi; Miura, Satoru; Watanabe, Kageaki; Koreeda, Yoshifusa; Ono, Akira; Furuya, Naoki; Misumi, Toshihiro; Hayakawa, Kazushige; Ogo, Etsuyo; Okamoto, Hiroaki
Cross-over adjusted overall survival for amivantamab plus chemotherapy vs chemotherapy in first-line EGFR exon-20 insertion NSCLC

与化疗相比，阿曼曲妥珠单抗联合化疗在一线EGFR外显子20插入性非小细胞肺癌中的交叉校正总生存期

ANNALS OF ONCOLOGY
IF65.4
2024-12-011
PRE
Lu, S.; Zhou, C.; Cho, B. C.; Ono, A.; Hayashi, H.; Majem, M.; Lee, S-H.; Richardson, G.; Sabari, J. K.; Girard, N.; Sanborn, R. E.; Mansfield, A. S.; Buyukkaramikli, N.; Perualila, N.; Acharya, S.; Chandler, C.; Dearden, L.; Agrawal, T.; Baig, M.; Park, K.
A phase II study of ME2136 (Asenapine Maleate) plus standard antiemetic therapy for patients, including diabetic patients, receiving cisplatin-based chemotherapy

ME2136 (马来酸阿塞那平) 加标准止吐治疗的II期研究，用于接受基于顺铂的化疗的患者，包括糖尿病患者

INVESTIGATIONAL NEW DRUGS
IF2.7
2024-10-260
PRE
Hamauchi, Satoshi; Yasui, Hirofumi; Yokota, Tomoya; Tsushima, Takahiro; Fushiki, Kunihiro; Naito, Tateaki; Ono, Akira; Kado, Nobuhiro; Onozawa, Yusuke; Murakami, Haruyasu; Takahashi, Toshiaki; Hirashima, Yasuyuki; Mori, Keita; Yamazaki, Kentaro
Biomarker analysis of plasma samples in YAMATO study: A randomized phase II trial comparing switching treatment of osimertinib following 8 months of afatinib (A) and osimertinib alone (B) in untreated advanced NSCLC patients with common EGFR mutation (TORG1939/WJOG12919L)

YAMATO研究中的血浆样本生物标志物分析：一项比较在携带常见EGFR突变（TORG1939/WJOG12919L）的未经治疗晚期NSCLC患者中，接受阿法替尼（A）治疗8个月后换用奥希替尼与单独使用奥希替尼（B）的随机II期试验。

ANNALS OF ONCOLOGY
IF65.4
2024-09-010
PRE
Yoshioka, H.; Nakamura, A.; Sakai, K.; Nishio, K.; Yonesaka, K.; Misumi, T.; Yokoyama, T.; Itani, H.; Tachihara, M.; Kanemura, H.; Akamatsu, H.; Ono, A.; Ishikawa, H.; Yamamoto, N.; Okamoto, H.; Kurata, T.
Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions
NEW ENGLAND JOURNAL OF MEDICINE
IF78.5
2023-11-3091
PRE
Zhou, Caicun; Tang, Ke-Jing; Cho, Byoung Chul; Liu, Baogang; Paz-Ares, Luis; Cheng, Susanna; Kitazono, Satoru; Thiagarajan, Muthukkumaran; Goldman, Jonathan W.; Sabari, Joshua K.; Sanborn, Rachel E.; Mansfield, Aaron S.; Hung, Jen-Yu; Boyer, Michael; Popat, Sanjay; Mourao Dias, Josiane; Felip, Enriqueta; Majem, Margarita; Gumus, Mahmut; Kim, Sang-we; Ono, Akira; Xie, John; Bhattacharya, Archan; Agrawal, Trishala; Shreeve, S. Martin; Knoblauch, Roland E.; Park, Keunchil; Girard, Nicolas; PAPILLON Investigators
OSIRAM-1: A multicenter, open label, randomized phase II study of osimertinib plus ramucirumab versus osimertinib alone as initial chemotherapy for EGFR mutation-positive non-squamous non-small cell lung cancer (TORG1833)
ANNALS OF ONCOLOGY
IF65.4
2023-10-012
PRE
Nakahara, Y.; Kato, T.; Isomura, R.; Misumi, T.; Tamiya, M.; Yoh, K.; Furuya, N.; Ono, A.; Takiguchi, Y.; Koyama, K.; Ikeda, S.; Watanabe, K.; Tokito, T.; Seki, N.; Imai, H.; Shukuya, T.; Shibata, Y.; Hosokawa, S.; Kozuki, T.; Okamoto, H.
Immunohistochemical analysis of B7-H3 expression in patients with lung cancer following various anti-cancer treatments

不同抗癌治疗后肺癌患者B7-H3表达的免疫组织化学分析

INVESTIGATIONAL NEW DRUGS
IF2.7
2023-04-103
PRE
Omori, Shota; Muramatsu, Koji; Kawata, Takuya; Miyawaki, Eriko; Miyawaki, Taichi; Mamesaya, Nobuaki; Kawamura, Takahisa; Kobayashi, Haruki; Nakashima, Kazuhisa; Wakuda, Kazushige; Ono, Akira; Kenmotsu, Hirotsugu; Naito, Tateaki; Murakami, Haruyasu; Sugino, Takashi; Takahashi, Toshiaki
Association between oligo-residual disease and patterns of failure during EGFR-TKI treatment in EGFR-mutated non-small cell lung cancer: a retrospective study

EGFR突变的非小细胞肺癌egfr-tki治疗过程中寡残留病与失败模式的关系: 一项回顾性研究

BMC CANCER
IF3.4
2021-11-194
OAAI
Miyawaki, Taichi; Kenmotsu, Hirotsugu; Kodama, Hiroaki; Nishioka, Naoya; Miyawaki, Eriko; Mamesaya, Nobuaki; Kobayashi, Haruki; Omori, Shota; Ko, Ryo; Wakuda, Kazushige; Ono, Akira; Naito, Tateaki; Murakami, Haruyasu; Mori, Keita; Harada, Hideyuki; Endo, Masahiro; Takahashi, Kazuhisa; Takahashi, Toshiaki

研究方向

暂未获取到该数据
T
Tateaki Naito
H 指数:43论文数:475被引数:8,098
H
Hirotsugu Kenmotsu
H 指数:41论文数:504被引数:8,020
T
Toshiaki Takahashi
H 指数:55论文数:653被引数:1.4万
H
Haruyasu Murakami
H 指数:49论文数:507被引数:9,255
K
Kazushige Wakuda
H 指数:30论文数:189被引数:2,552
S
Shota Omori
H 指数:23论文数:133被引数:1,537
M
Masahiro Endo
H 指数:60论文数:846被引数:1.5万
H
Haruki Kobayashi
H 指数:22论文数:206被引数:1,456
N
Nobuaki Mamesaya
H 指数:19论文数:179被引数:976
K
Keita Mori
H 指数:44论文数:372被引数:6,446